全部

1·Docetaxel is a newly developed taxoid anticancer agent.

多西他赛是新的紫杉类抗癌药物。

2·Data suggest that docetaxel (t) may add to the efficacy of PF.

数据表明多西他赛(T)可能增加PF方案的有效性。

3·Finally, I will conclude by discussing new trials with docetaxel.

最后，我将总结有关泰索帝治疗胃癌的临床研究。

4·OS benefit is obtained with early use of pemetrexed but not docetaxel;

早期应用培美曲赛对OS是获益的而不是多西他赛；

5·Objective HPLC method was established for injection of docetaxel content.

目的建立了HPLC法测定注射用多西他赛的含量。

6·Results Determines of docetaxel quantity 97.4% to sample of the indication.

结果测定多西他赛注射液样品中多西他赛含量为标示量的97.4%。

7·Docetaxel, when combined with cisplatin, results in very respectable response rate.

泰索帝与顺铂联合可产生较佳的缓解率。

8·In 2005, docetaxel was ranked 34, and three other oncologic blockbusters made the top 50 list.

在2005年，紫杉醇名列34位，而其它三个肿瘤要的拳头产品进入销量榜前50强。

9·These results indicate that interaction between docetaxel and cisplatin is highly schedule dependent.

多烯紫杉醇与顺铂的相互作用具有高度给药顺序依赖性。

10·In addition, the present invention also discloses the preparation process of the docetaxel crystal form.

此外，本发明还公开了该多烯紫杉醇晶型的制备方法。

多西他赛

1·Data suggest that docetaxel (t) may add to the efficacy of PF.

数据表明多西他赛(T)可能增加PF方案的有效性。

2·Objective To evaluate the efficacy and toxicity of docetaxel plus oxaliplatin in the treatment of platinum resistance advanced epithelia ovary cancer.

目的评价国产多西他赛联合奥沙利铂作为铂类耐药的晚期卵巢上皮癌解救化疗的疗效和毒性。

3·Objective to evaluate the recent efficacy and toxicity of docetaxel combined with cisplatin and 5-fu in the treatment of patients with metastatic esophageal cancer.

目的观察多西他赛联合顺铂和5 -氟脲嘧啶方案治疗转移性食管癌的近期疗效和毒副反应。

4·Docetaxel is a newly developed taxoid anticancer agent.

多西他赛是新的紫杉类抗癌药物。

5·Such findings confirm the data from Fidias et al with respect to docetaxel, and the 4 studies had a similar design.

这种研究发现证实了来自Fidias等关于多西他赛的研究结果，而且4项大型的临床研究都有相似的试验设计。

多西紫杉醇

1·Objective To investigate the efficacy and safety of domestic docetaxel plus cisplatin regimen in patients with advanced non-small-cell lung cancer (NSCLC).

目的评价国产多西紫杉醇治疗晚期非小细胞肺癌的临床疗效和安全性。

2·Background and Objective: Docetaxel combined with cisplatin is established as first-line therapy for advanced non-small cell lung cancer (NSCLC).

背景与目的：多西紫杉醇联合顺铂被确定为治疗晚期非小细胞肺癌的一线方案之一。

3·As the current evidence shows, pemetrexed has similar efficacy to docetaxel for advanced NSCLC patients, but it has fewer side effects of neutropenia, febrile neutropenia and alopecia.

结论当前证据显示，培美曲塞与多西紫杉醇治疗晚期NSCLC的疗效相当，但可减少中性粒细胞减少、粒细胞性发热和脱发等不良反应。